Stockscreener 앱 받기
13.80
1.22%
-0.18
전일 마감가:
$13.98
열려 있는:
$13.76
하루 거래량:
463.00K
Relative Volume:
0.25
시가총액:
$830.04M
수익:
$439.00K
순이익/손실:
$-105.64M
주가수익비율:
-7.6667
EPS:
-1.8
순현금흐름:
$-60.70M
1주 성능:
+0.07%
1개월 성능:
-16.71%
6개월 성능:
-43.52%
1년 성능:
-72.83%
1일 변동 폭
$13.64
$13.93
1주일 범위
$13.26
$14.30
52주 변동 폭
$13.26
$50.89
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
13.80 | 840.87M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.62 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
807.74 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.29 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
796.17 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
168.94 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-10 | 개시 | Stifel | Buy |
| 2025-09-10 | 개시 | Truist | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Will Janux Therapeutics Inc. stock benefit from infrastructure spendingDividend Growth Stocks & High Return Trading Portfolio - ulpravda.ru
Why Janux Therapeutics Inc. stock remains resilientAutomated Trading Signals & Capital Planning and Optimization - ulpravda.ru
BofA Adjusts Price Target on Janux Therapeutics to $35 From $49, Maintains Buy Rating - MarketScreener
Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month LowWhat's Next? - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Nasdaq 100 Index Biotech Innovator - Kalkine Media
Janux Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Pre-market Movers: RSLS, STSS, VERO, KTTA... - RTTNews
Andrew Hollman Meyer Sells 1,879 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics CEO Campbell sells $110k in stock By Investing.com - Investing.com Canada
Janux Therapeutics’ CMO McIver sells $37k in shares By Investing.com - Investing.com Australia
Janux Therapeutics’ CMO McIver sells $37k in shares - Investing.com
Janux Therapeutics CBO Meyer sells $25,798 in stock By Investing.com - Investing.com Canada
Janux Therapeutics CSO sells $34k in shares By Investing.com - Investing.com Canada
Maria Dobek, Janux Therapeutics VP, sells $20k in shares By Investing.com - Investing.com UK
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 2,714 Shares of Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) CEO David Alan Campbell Sells 8,072 Shares of Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 1,462 Shares - MarketBeat
(JANX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowHere's What Happened - MarketBeat
Is Janux Therapeutics Inc a good long term investmentEarnings Call Summaries & Exceptional Return Capital - earlytimes.in
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Janux Therapeutics Earnings Notes - Trefis
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Finviz
Why Wall Street sees big potential in Janux Therapeutics, Inc. (JANX) - MSN
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Janux Therapeutics Inc (JANX) - The Globe and Mail
What analysts say about Janux Therapeutics Inc stockHead and Shoulders Patterns & High Yield Trading Signals - earlytimes.in
Janux Therapeutics Pipeline Remains on Track as JANX008 Advances, Wedbush Says - marketscreener.com
Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence - Nasdaq
Janux completes phase 1a dose-escalation for EGFR cancer drug By Investing.com - Investing.com UK
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - New Castle News
Here are the most and least likely M&A targets in biotech, according to Truist - Seeking Alpha
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Why Janux Therapeutics Inc. stock is favored by top institutions2025 Buyback Activity & Free Reliable Trade Execution Plans - Улправда
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Market Rankings: Is Janux Therapeutics Inc. stock supported by strong fundamentalsDay Trade & Verified High Yield Trade Plans - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Big Money Moves: Is Janux Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Summary & Technical Buy Zone Confirmations - Улправда
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Why Janux Therapeutics Inc. stock remains a top recommendationMarket Rally & AI Driven Stock Movement Reports - Улправда
Is Janux Therapeutics Inc. stock a contrarian buyMarket Activity Summary & Daily Chart Pattern Signals - Улправда
Buyout Rumor: Why Janux Therapeutics Inc. stock is favored by top institutionsWeekly Profit Report & Capital Efficient Trade Techniques - Улправда
Barclays Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Barclays Maintains Janux Therapeutics (JANX) Overweight Recommendation - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month LowHere's What Happened - MarketBeat
Squarepoint Ops LLC Raises Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Wyckoff Accumulation Phase Possible in National Standard India LimitedBlue Chip Stock Analysis & Low Cost Capital Growth - earlytimes.in
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - AOL.com
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.77%
자본화:
|
볼륨(24시간):